Type II monocytes modulate T cell–mediated central nervous system autoimmune disease

Weber, Martin S, Prod'homme, Thomas, Youssef, Sawsan, Dunn, Shannon E, Rundle, Cynthia D, Lee, Linda, Patarroyo, Juan C, Stüve, Olaf +3 more·2007·Nature Medicine
DOI 10.1038/nm1620

Cited by (441)

Items 301–400 of 441

  1. Discovery of new macrophage M2 polarization modulators as multiple sclerosis treatment agents that enable the inflammation microenvironment remodeling
    Jinxin Che, Dan Li, Wenxiang Hong, Longling Wang, Yu Lian Guo, Mingfei Wu, Jialiang Lu, Lexian Tong, Qinjie Weng, Jiajia Wang et al. · 2022 · European Journal of Medicinal Chemistry
  2. Glatiramer acetate and therapeutic peptide vaccines for multiple sclerosis
    Jill B. Conner · 2014 · Journal of Autoimmunity and Cell Responses
  3. Complex Drugs and Biologics: Scientific and Regulatory Challenges for Follow-on Products
    J. Michael Nicholas · 2012 · Drug Information Journal
  4. Protective effect of ulinastatin on severe pulmonary infection under immunosuppression and its molecular mechanism
    Wenshuai Liu, Guozhong Pang, Shengyan Wang, Aiqin Sun · 2017 · Experimental and Therapeutic Medicine
  5. Predictive cytokine biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
    Reuben Mari Valenzuela, M. Kaufman, Konstantin E. Balashov, Kouichi Ito, Steven G. Buyske, Suhayl S. Dhib-Jalbut · 2016 · Journal of Neuroimmunology
  6. Neuroinflammation responses and neurodegeneration in multiple sclerosis
    Serge Nataf · 2009 · Revue Neurologique
  7. Glatiramer Acetate‐Specific Antibody Titres in Patients with Relapsing / Remitting Multiple Sclerosis and in Experimental Autoimmune Encephalomyelitis
    Roberto Bomprezzi, R. Schaefer, Van R. Reese, Aditya Misra, Timothy L. Vollmer, Mrinalini Kala · 2011 · Scandinavian Journal of Immunology
  8. Continuous retinoic acid induces the differentiation of mature regulatory monocytes but fails to induce regulatory dendritic cells
    Zachary VanGundy, Mireia Guerau‐de‐Arellano, Julie D Baker, Heather R. Strange, Susan Olivo‐Marston, Dillon C. Muth, Tracey L. Papenfuss · 2014 · BMC Immunology
  9. Tempering antigen-presenting cells in multiple sclerosis
    Thomas Prod’homme, Scott S. Zamvil · 2008 · Nature Medicine
  10. Update on multiple sclerosis, its diagnosis and treatments
    Anne Haney Cross, Kevin A. Cross, Laura M. Piccio · 2012 · Clinical Chemistry and Laboratory Medicine (CCLM)
  11. Protection from EAE by IL‐4Rα−/− macrophages depends upon T regulatory cell involvement
    Paula Elizabeth Keating, David O’Sullivan, Joanna Tierney, Diane Kenwright, Sara Miromoeini, Lina Mawasse, Frank Brombacher, Anne Camille La Flamme · 2009 · Immunology and Cell Biology
  12. Inhibition of experimental autoimmune uveitis by amino acid copolymers
    Hongen Yin, Barbara P. Vistica, Chi‐Chao Chan, Jack L. Strominger, Igal Gery · 2009 · Journal of Neuroimmunology
  13. Glatiramoids
    Vera Weinstein, Rivka Schwartz, Iris Grossman, Benjamin J. Zeskind, J. Michael Nicholas · 2015 · AAPS advances in the pharmaceutical sciences series
  14. Myeloperoxidase Molecular MRI Reveals Synergistic Combination Therapy in Murine Experimental Autoimmune Neuroinflammation
    Anning Li, Yue Wu, Benjamin Pulli, Gregory R. Wojtkiewicz, Yoshiko Iwamoto, Cuihua Wang, Jinghui Li, Muhammad Yassar Jazaib Ali, Xiaoyuan Feng, Zhenwei Yao et al. · 2019 · Radiology
  15. Serial combination therapy: is immune modulation in multiple sclerosis enhanced by initial immune suppression?
    Amit Bar‐Or, Joël Oger, E Gibbs, Masaaki Niino, Tarek Aziz, Christel Renoux, Sudabeh Alatab, Fu‐Dong Shi, Denise I. Campagnolo, F. Jalili et al. · 2009 · Multiple Sclerosis Journal
  16. Glatiramer acetate treatment does not modify the clinical course of (NZB x BXSB)F1 lupus murine model
    Paula Borel, Mahdia Benkhoucha, Martin S. Weber, Scott S. Zamvil, Marie‐Laure Santiago‐Raber, Patrice H. Lalive · 2008 · International Immunology
  17. Immunomodulatory drug treatment in multiple sclerosis
    Rina Aharoni · 2010 · Expert Review of Neurotherapeutics
  18. Comparing methods for ex vivo characterization of human monocyte phenotypes and in vitro responses
    Lisa Johnston, Scott A. Harding, Anne Camille La Flamme · 2015 · Immunobiology
  19. Glatiramer Acetate for the Treatment of Multiple Sclerosis: From First-Generation Therapy to Elucidation of Immunomodulation and Repair
    Rina Aharoni, Ron Milo, Ruth Arnon · 2024 · Pharmacological Reviews
  20. Glatiramer acetate ameliorates experimental autoimmune neuritis
    Cun‐Jin Zhang, Hui Zhai, Yaping Yan, Junwei Hao, Minshu Li, Wei‐Na Jin, Ning Su, Timothy L Vollmer, Fu‐Dong Shi · 2013 · Immunology and Cell Biology
  21. Immunomodulation of Antigen Presenting Cells Promotes Natural Regulatory T Cells That Prevent Autoimmune Diabetes in NOD Mice
    Martin J. Richer, Danielle J. Lavallée, Iryna Shanina, Marc Steven Horwitz · 2012 · PLoS ONE
  22. Expression and functional activity of chemokine receptors in glatiramer acetate–specific T cells isolated from multiple sclerosis patient receiving the drug glatiramer acetate
    Rune Alexander Høglund, Anne Lise Karlsgot Hestvik, Trygve Holmøy, Azzam A. Maghazachi · 2010 · Human Immunology
  23. Role of Natural Killer Cells in Multiple Sclerosis
    Azzam A. Maghazachi · 2012 · ISRN Immunology
  24. The Innate Immune Response: An Important Partner in Shaping Coxsackievirus-Mediated Autoimmunity
    Martin J. Richer, Marc Steven Horwitz · 2009 · Journal of Innate Immunity
  25. Glatiramer Acetate Attenuates Pro-Inflammatory T Cell Responses but Does Not Directly Protect Neurons from Inflammatory Cell Death
    Alexander M. Herrmann, Kerstin Göbel, Ole J. Simon, Nico Melzer, Michael Klaus Schuhmann, Max‐Philipp Stenner, Andreas Weishaupt, Christoph Kleinschnitz, Stefan Bittner, Patrick Meuth et al. · 2010 · American Journal Of Pathology
  26. B-Cell Targeting Agents in the Treatment of Multiple Sclerosis
    Tiffany J. Braley, Benjamin M. Segal · 2013 · Current Treatment Options in Neurology
  27. B Cell Receptor Recognition of Glatiramer Acetate is Required for Efficacy through Antigen Presentation and Cytokine Production
    Leila J Jackson Sean Selva · 2014 · Journal of Clinical & Cellular Immunology
  28. Glatiramer Acetate
    Ruth Arnon, Rina Aharoni · 2016 · Elsevier eBooks
  29. Statins in multiple sclerosis
    Martin S. Weber, Emmanuelle L. Waubant, Scott S. Zamvil · 2011 · Cambridge University Press eBooks
  30. Beneficial Effect of Glatiramer Acetate Treatment on Syndecan-1 Expression in Dextran Sodium Sulfate Colitis
    Doron Yablecovitch, Maytal Shabat-Simon, Rina Aharoni, Raya Eilam, Ori Jacob Brenner, Ruth Arnon · 2011 · Journal of Pharmacology and Experimental Therapeutics
  31. Inflammation induced neurological handicap processes in multiple sclerosis: new insights from preclinical studies
    Klaus G. Petry, Bruno Brochet, Vincent Dousset, Jean Rodolphe Vignes, Claudine Boiziau · 2010 · Journal of Neural Transmission
  32. Glatiramer Acetate Guards Against Rapid Memory Decline During Relapsing-Remitting Experimental Autoimmune Encephalomyelitis
    Patrizia LoPresti · 2014 · Neurochemical Research
  33. Processing and presentation of (pro)‐insulin in the MHC class II pathway: the generation of antigen‐based immunomodulators in the context of type 1 diabetes mellitus
    Timo Burster, Bernhard Otto Boehm · 2010 · Diabetes/Metabolism Research and Reviews
  34. IMMUNOPATHOGENESIS OF MULTIPLE SCLEROSIS
    Amer M. Awad, Olaf Stüve · 2010 · CONTINUUM Lifelong Learning in Neurology
  35. Amelioration of experimental autoimmune encephalomyelitis by in vivo reprogramming of macrophages using pro-resolving factors
    Thierry Gauthier, Omayra Martin-Rodriguez, Cécile Chagué, Anna Daoui, Adam Ceroi, Alexis Varin, Francis Bonnefoy, Séverine Valmary‐Degano, Mélanie Couturier, Susanne Behlke et al. · 2023 · Journal of Neuroinflammation
  36. Plasma Lipoproteins in Brain Inflammatory and Neurodegenerative Diseases
    Armando Sena, Carlos Capela, Camila Nóbrega, Véronique Ferret-Sena, Elisa Maria Campos, Rui Pedros · 2012 · InTech eBooks
  37. Antigen-specific therapies in multiple sclerosis
    Paul Steven Giacomini, Amit Bar‐Or · 2009 · Expert Opinion on Emerging Drugs
  38. HLA-A∗03:01 as predictive genetic biomarker for glatiramer acetate treatment response in multiple sclerosis: a retrospective cohort analysis
    Brian C. Zhang, Tilman Schneider‐Hohendorf, Rebecca Elyanow, Béatrice Pignolet, Simon Falk, Christian Wünsch, Marie Deffner, Erik C. Yusko, Damon May, Daniel E. Mattox et al. · 2025 · EBioMedicine
  39. Mechanisms of antigen-induced reversal of CNS inflammation in experimental demyelinating disease
    Jian Li, Lisen Lu, Kyle Binder, Jian Xiong, Lilin Ye, Yan H. Cheng, Sonia S Majri-Morrison, Wei Lü, Jae Woo Lee, Zhihong Zhang et al. · 2023 · Science Advances
  40. Macrophage-Specific Chemokines Induced via Innate Immunity by Amino Acid Copolymers and Their Role in EAE
    Joseph Kovalchin, Jeffrey I. Krieger, Michelle Genova, Norio Kawamoto, Michael E. Augustyniak, K. Collins, Troy Bloom, Allyson Masci, Tara Hittinger, Ingrid Dufour et al. · 2011 · PLoS ONE
  41. Glatiramer acetate (GA) prevents TNF-α-induced monocyte adhesion to primary endothelial cells through interfering with the NF-κB pathway
    Guoqian Wei, Xueyan Zhang, Zhendong Su, Xueqi Li · 2014 · Biochemical and Biophysical Research Communications
  42. - Multiple Sclerosis Basics
    Michelle H. Cameron, Marcia L. Finlayson, Jürg Kesselring · 2012 · CRC Press eBooks
  43. Synthetic Cationic Autoantigen Mimics Glatiramer Acetate Persistence at the Site of Injection and Is Efficacious Against Experimental Autoimmune Encephalomyelitis
    Jimmy Y. Song, J. Daniel Griffin, Nicholas R. Larson, Matthew A. Christopher, Charles Russell Middaugh, Cory J. Berkland · 2021 · Frontiers in Immunology
  44. Combining statins with interferon beta in multiple sclerosis: think twice, it might not be all right
    Scott S. Zamvil, Lawrence Steinman · 2011 · The Lancet Neurology
  45. T cell receptors in an IL-10-secreting amino acid copolymer-specific regulatory T cell line that mediates bystander immunosuppression
    Hong Zhang, Joel N. H. Stern, Jack L. Strominger · 2009 · Proceedings of the National Academy of Sciences
  46. Safety, Pharmacokinetic, and Pharmacodynamic Evaluations of PI-2301, a Potent Immunomodulator, in a First-in-Human, Single-Ascending-Dose Study in Healthy Volunteers
    Joseph Kovalchin, Jeffrey I. Krieger, Kathy S. Collins, Michelle Genova, Michael E. Augustyniak, Allyson Masci, Tony Avril, Gwenola Gandon, Alain A. Patat, Nicolas Fauchoux et al. · 2010 · The Journal of Clinical Pharmacology
  47. Modulating acute neuroinflammation in intracerebral hemorrhage: the potential promise of currently approved medications for multiple sclerosis
    Jarred A. Napier, Lucas Rose, Opeolu M Adeoye, Edmond A. Hooker, Kyle B. Walsh · 2019 · Immunopharmacology and Immunotoxicology
  48. Computational modeling of brain pathologies: the case of multiple sclerosis
    Francesco Pappalardo, Abdul-Mateen Rajput, Santo Motta · 2016 · Briefings in Bioinformatics
  49. 29 gauge needles improve patient satisfaction over 27 gauge needles for daily glatiramer acetate injections
    Glenski · 2009 · Drug Healthcare and Patient Safety
  50. 4R-cembranoid protects neuronal cells from oxygen–glucose deprivation by modulating microglial cell activation
    Hefei Fu, Jiapeng Wang, Jie Wang, Langni Liu, Jianxiong Jiang, Jiukuan Hao · 2021 · Brain Research Bulletin
  51. Amino Acid Copolymers That Alleviate Experimental Autoimmune Encephalomyelitis In Vivo Interact with Heparan Sulfates and Glycoprotein 96 in APCs
    Paul-Albert Koenig, Eric Spooner, Norio Kawamoto, Jack L. Strominger, Hidde L. Ploegh · 2013 · The Journal of Immunology
  52. Morphological evidence of the beneficial role of immune system cells in a rat model of surgical brain injury
    Małgorzata Frontczak‐Baniewicz, Dorota Sulejczak, Jarosław Andrychowski, Magdalena Gewartowska, Milena Laure‐Kamionowska, Wojciech Kozłowski · 2013 · Folia Neuropathologica
  53. Type II Activation of Macrophages and Microglia by Immune Complexes Enhances Th17 Biasing in an IL-6-Independent Manner
    Sarrabeth Stone, Anne Camille La Flamme · 2016 · PLoS ONE
  54. Compositional differences between Copaxone and Glatopa are reflected in altered immunomodulation ex vivo in a mouse model
    Iris Grossman, Sarah E. Kolitz, Arthur Komlosh, Benjamin J. Zeskind, Vera Weinstein, Daphna Laifenfeld, Adrian Gilbert, Oren Bar‐Ilan, Kevin D. Fowler, Tal H. Hasson et al. · 2017 · Annals of the New York Academy of Sciences
  55. Expression of STAT ‐ and T‐cell‐related genes in women with first‐line treatment of relapsing‐remitting multiple sclerosis
    Ludmiła Szewczak, Maja Machcińska, Magdalena Kierasińska, Urszula Zawadzka-Więch, Marta Maruszewska‐Cheruiyot, Pawel Marek Majewski, Anna G. Karlińska, Rafał Rola, Katarzyna Donskow‐Łysoniewska · 2024 · Scandinavian Journal of Immunology
  56. Induction of apoptosis in CD4(+) T-cells is linked with optimal treatment response in patients with relapsing-remitting multiple sclerosis treated with Glatiramer acetate
    Marina Kleopatra Boziki, Roza Lagoudaki, Pâmela Melo, Foteini Kanidou, Christos Bakirtzis, Ioannis Nikolaidis, Eleni Grigoriadou, Theodora Afrantou, Theano Tatsi, Stavroula Matsi et al. · 2019 · Journal of the Neurological Sciences
  57. A modified superantigen rescues Ly6G−CD11b+blood monocyte suppressor function and suppresses antigen-specific inflammation in EAE
    Clare Y. Slaney, Aras Toker, John D. Fraser, Jacquie L. Harper, B. Thomas Bäckström · 2013 · Autoimmunity
  58. STATs, promising targets for the treatment of autoimmune and inflammatory diseases
    Xinlian He, Pingxian Liu, Youfu Luo, Xin-Yuan Fu, Tao Yang · 2024 · European Journal of Medicinal Chemistry
  59. The role of dendritic cells in the generation of CD4+ CD25HI Foxp3+ T cells induced by amino acid copolymers
    Norio Kawamoto, Hidenori Ohnishi, Naoyuki Kondo, Jack L. Strominger · 2012 · International Immunology
  60. Once‐daily glatiramer acetate decreases magnetic resonance imaging disease activity in Japanese patients with relapsing–remitting multiple sclerosis
    Takashi Yamamura, Natalia Ashtamker, David Ladkani, Toshiyuki Fukazawa, Hideki Houzen, Masami Tanaka, Toshiro Miura, Volker A. Knappertz · 2017 · Clinical and Experimental Neuroimmunology
  61. Preventing Viral‐induced Type 1 Diabetes
    Martin J. Richer, Marc Steven Horwitz · 2009 · Annals of the New York Academy of Sciences
  62. Multiple linked quantitative trait loci within the Tmevd2/Eae3 interval control the severity of experimental allergic encephalomyelitis in DBA/2J mice
    Karen M. Spach, Laure K. Case, Rajkumar Noubade, Carolyn Petersen, Benjamin D. McElvany, Nathan J. Zalik, William F. Hickey, Elizabeth P. Blankenhorn, Cory Teuscher · 2010 · Genes and Immunity
  63. Genetically modified hematopoietic stem/progenitor cells that produce IL-10–secreting regulatory T cells
    Sze‐Ling Ng, Ester Leno‐Durán, Dibyendu Samanta, Steven C. Almo, Jack L. Strominger · 2019 · Proceedings of the National Academy of Sciences
  64. Immunomodulatory peptidomimetics for multiple sclerosis therapy—the story of glatiramer acetate (Copaxone)
    Rina Aharoni · 2022 · Elsevier eBooks
  65. Repurposing of glatiramer acetate to treat cardiac ischemia in rodent models
    Gal Aviel, Jacob Elkahal, Kfir Baruch Umansky, Hanna Bueno-Levy, Zachary Petrover, Yulia Kotlovski, Daria Lendengolts, David Kain, Tali Shalit, Lingling Zhang et al. · 2024 · Nature Cardiovascular Research
  66. Failure of glatiramer acetate to modify the peripheral T cell repertoire of relapsing–remitting multiple sclerosis patients
    Laureline Berthelot, Patrick Miqueu, Ségolène Pettré, Marina Guillet, Julien Moynard, Sandrine Wiertlewski, Fabienne Lefrère, Sophie Brouard, Jean‐Paul Soulillou, David Axel Laplaud · 2010 · Clinical Immunology
  67. Monocyte recruitment to the inflamed central nervous system: migration pathways and distinct functional polarization
    Daniela C. Ivan, Sabrina Walthert, Giuseppe Locatelli · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
  68. Innate immunomodulation with MIS416: mechanism of action in experimental autoimmune encephalomyelitis
    Madeleine P. J. White · 2015
  69. A narrative review on the safety of glatiramer acetate in multiple sclerosis: focus on Europe
    Refik Pul, Jelena Škuljec, Santosh B Shirol, Riyaz Ahmed Saboor, Christoph Kleinschnitz · 2025 · Therapeutic Advances in Chronic Disease
  70. Experimentation of Heterocycles (2013‐22) as Potent Pharmacophores in Drug Design of Multiple Sclerosis
    Atukuri Dorababu · 2025 · Drug Development Research
  71. Imaging the execution phase of neuroinflammatory disease models
    Adrian-Minh Schumacher, Thomas Misgeld, Martin Kerschensteiner, Nicolas Snaidero · 2019 · Experimental Neurology
  72. Role of effector T cells in multiple sclerosis
    Norio Chihara · 2020 · Clinical and Experimental Neuroimmunology
  73. Treatment with glatiramer acetate in APPswe/PS1dE9 mice at an early stage of Alzheimer’s disease prior to amyloid-beta deposition delays the disease’s pathological development and ameliorates cognitive decline
    Zengyong Huang, Zhuo Gong, Yongtai Lin, Fan Yang, Weiping Chen, Shaotong Xiang, Yuedong Huang, Hao Xiao, Shuwen Xu, Jinhai Duan · 2024 · Frontiers in Aging Neuroscience
  74. Ex vivo expansion of regulatory T cell and T helper 2 cells using a hematosphere culture
    Dong Hwan Kim, Parkyong Song, Jung-Hwa Han, Jin Hur · 2020 · Immunobiology
  75. Glatiramer acetate treatment inhibits inflammatory responses and improves survival in a mice model of cecal ligation and puncture-induced sepsis
    Elahe Maleki, Mohammad Sheibani, Sadaf Nezamoleslami, Ahmad Reza Dehpour, Nasrin Takzaree, Hamed Shafaroodi · 2021 · Journal of Basic and Clinical Physiology and Pharmacology
  76. Testing effects of glatiramer acetate and fingolimod in an infectious model of CNS immune surveillance
    Cyd M. Castro-Rojas, Krystin L Deason, Rehana Z. Hussain, Liat Hayardeny, Petra D. Cravens, Felix Yarovinsky, Todd N. Eagar, Benjamine Arellano, Olaf Stüve · 2014 · Journal of Neuroimmunology
  77. Glatiramer Acetate Modifies the Immune Profiles of Monocyte-Derived Dendritic Cells In Vitro Without Affecting Their Generation
    Jelena Škuljec, Maryam Sardari, Chuanxin Su, Julia Müller-Dahlke, Vikramjeet Singh, Marija M. Janjic, Christoph Kleinschnitz, Refik Pul · 2025 · International Journal of Molecular Sciences
  78. Translational Characterization of the Glia Role in Multiple Sclerosis
    Dumitru Ciolac, Stanislav A. Groppa, Gabriel González‐Escamilla · 2021 · Neuromethods
  79. Therapy
    Trevor John Kilpatrick, Richard M. Ransohoff, Steve L Wesselingh · 2009 · Cambridge University Press eBooks
  80. A place of first-line drugs in treatment of multiple sclerosis
    Dmitriy S. Kasatkin · 2016 · S S Korsakov Journal of Neurology and Psychiatry
  81. Microglia
    Dimitrios Davalos, Katerina Akassoglou, Astrid E. Cardona · 2020 · Elsevier eBooks
  82. Innate immunity and biomarkers of multiple sclerosis relapse versus remission
    Meltem Karadeniz, Robb Wesselingh, Padmakrishnan C. Jayakrishnan, Richard P. Sequeira, Anneke van der Walt, Helmut Butzkueven, Mastura Monif · 2026 · Autoimmunity Reviews
  83. Microglia
    Astrid E. Cardona, Richard M. Ransohoff, Katerina Akassoglou · 2013 · Elsevier eBooks
  84. Inconsistent Effects of Glatiramer Acetate Treatment in the 5xFAD Mouse Model of Alzheimer’s Disease
    Berke Karaahmet, John A. Olschowka, M. Kerry O’Banion · 2023 · Pharmaceutics
  85. Glatiramer acetate to treat multiple sclerosis
    Jenny Guerre, Corey C. Ford · 2011 · Cambridge University Press eBooks
  86. New Directions in Multiple Sclerosis Therapy: Matching Therapy with Pathogenesis
    Jack Perry Antel · 2010 · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
  87. Your nose knows how to target brain inflammation
    Ryan C. Winger, Scott S. Zamvil · 2016 · Brain
  88. Immunomodulation in the Nervous and Vascular Systems During Inflammation and Autoimmunity: the Role of T Regulatory Cells
    Kokona Chatzantoni, Αthanasia Mouzaki · 2009 · Oxford University Press eBooks
  89. Neuro-inflammation:
    Joseph M. Antony, Christopher Power · 2009 · Cambridge University Press eBooks
  90. Prophylactic Glatiramer Acetate Treatment Positively Attenuates Spontaneous Opticospinal Encephalomyelitis
    Ümmügülsüm Koc, Steffen Haupeltshofer, Katharina Klöster, Seray Demir, Ralf Gold, Simon Faissner · 2023 · Cells
  91. High frequency of circulating non-classical monocytes is associated with stable remission in relapsing-remitting multiple sclerosis
    Misako Minote, Wakiro Sato, Kimitoshi Kimura, Atsuko Kimura, Youwei Lin, Tomoko Okamoto, Ryōsuke Takahashi, Takashi Yamamura · 2024 · Immunological Medicine
  92. Сhanges of the functional phenotype of circulating monocytes during pregnancy
    N. G. Bukhtueva, O. Yu. Leplina, Е. Ya. Shevela, Marina Aleksandrovna Tikhonova, Н. М. Пасман, Alexander A. Ostanin, Elena Removna Chernykh · 2025 · Medical Immunology (Russia)
  93. Innate origins of multiple sclerosis pathogenesis: Implications for computer‐assisted design of disease‐modifying therapies
    Nicholas S. Stoy · 2011 · Drug Development Research
  94. Macrophages and Microglia in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis
    Manoj Kumar Mishra, Voon Wee Yong · 2013 · Springer eBooks
  95. Mechanisms of Action of Glatiramer Acetate in the Treatment of Multiple Sclerosis
    William A. Sheremata, Yesica Campos · 2015 · Elsevier eBooks
  96. Myeloid Cells in Multiple Sclerosis
    Marilyn Wang, Sofia E. Caryotakis, Nagendra Kumar, Alan Vu Nguyen, Athena M. Soulika · 2019 · IntechOpen eBooks
  97. Using Experimental Autoimmune Encephalomyelitis to Identify Prospective Treatments for Multiple Sclerosis
    David O’Sullivan · 2012
  98. Mechanisms Involved in Type II Macrophage Activation and Effector Functions
    Marie Kharkrang · 2010
  99. Regulatory CD4+ and CD8+ T cells as candidates for regenerative therapies in a mouse model of multiple sclerosis
    Tina Leuenberger · 2012 · Universitätsbibliothek der FU Berlin Hochschulschriftenstelle u. Dokumentenserver
  100. Investigating the mechanism by which the atypical antipsychotic clozapine reduces disease in experimental autoimmune encephalomyelitis
    Pirooz Zareie · 2017